Home

STEVEN M KLOSK

CIK 1192621 · President & CEO · last filed 2026-01-13

STEVEN M KLOSK is a President & CEO who has filed 78 SEC Form 4 insider transactions across 5 companies since 2007. The most recent filing, for LSTA, was dated Jan 13, 2026. Across all open-market trades the lifetime net is −$72.5M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $156.2K across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$156.2K

Companies

5

Total Filings

78

Lifetime Open-Market Net

-$72.47M

Filer Profile

Reported Address
C/O LISATA THERAPEUTICS, INC.
110 ALLEN ROAD, 2ND FLOOR
BASKING RIDGE, NJ 07920
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
LSTA Director 95,815 $1.63 $156.2K $0 4 2026-01-13
Bolt Projects Holdings, Inc. (BSLKW) Delisted Director 57,500 $0.02 $1.2K $0 2 2024-11-27
LISATA THERAPEUTICS, INC. (CLBS) Delisted Director 10,093 $6.40 $64.6K $0 10 2022-01-12
CAMBREX CORP (CBM) Delisted President & CEO 163,706 — — -$72.51M 58 2019-12-05
LISATA THERAPEUTICS, INC. (NBS) Delisted Director 32,000 — — $39.9K 4 2015-06-04

Recent Filings

78 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-01-13 LSTA Grant (A) +30,456 $0 EDGAR
2025-01-13 LSTA Grant (A) +15,789 $0 EDGAR
2024-11-27 Bolt Projects Holdings, Inc. (BSLKW) Delisted Grant (A) +37,500 $0 EDGAR
2024-08-15 Bolt Projects Holdings, Inc. (BSLKW) Delisted Exer (M) +35,000 $0 EDGAR
2024-01-11 LSTA Grant (A) +19,480 $0 EDGAR
2023-01-11 LSTA Grant (A) +20,000 $0 EDGAR
2022-01-12 LISATA THERAPEUTICS, INC. (CLBS) Delisted Grant (A) +65,430 $0 EDGAR
2021-01-12 LISATA THERAPEUTICS, INC. (CLBS) Delisted Grant (A) +37,735 $0 EDGAR
2020-01-14 LISATA THERAPEUTICS, INC. (CLBS) Delisted Grant (A) +18,292 $60.0K EDGAR
2019-12-05 CAMBREX CORP (CBM) Delisted Mixed −113,706 -$13.39M EDGAR
Showing 1–10 of 78
Page 1 of 8
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.